These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28341370)

  • 21. Smoldering Multiple Myeloma: To Treat or Not to Treat.
    Kapoor P; Rajkumar SV
    Cancer J; 2019; 25(1):65-71. PubMed ID: 30694862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review.
    Maura F; Bolli N; Rustad EH; Hultcrantz M; Munshi N; Landgren O
    JAMA Oncol; 2020 Mar; 6(3):425-432. PubMed ID: 31830214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk Stratification and Treatment in Smoldering Multiple Myeloma.
    Lussier T; Schoebe N; Mai S
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rare Association between Sarcoidosis and Smoldering Multiple Myeloma: A Case Report.
    Learned BN; Nasiri-Ahad W; Davis JE; Desai AG; Chang A
    Cancer Invest; 2021 Nov; 39(10):880-884. PubMed ID: 34606401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Willrich MAV; Murray DL; Kyle RA
    Clin Biochem; 2018 Jan; 51():38-47. PubMed ID: 28479151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Smoldering Myeloma Treatment: Who, What, and When.
    Mejia Saldarriaga M; Rossi A
    Cancer J; 2021 May-Jun 01; 27(3):185-189. PubMed ID: 34549905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [CME: Multiple Myeloma - a Review].
    Bräutigam M; Biskup E
    Praxis (Bern 1994); 2018 Jul; 107(14):749-754. PubMed ID: 29969971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis.
    Visram A; Rajkumar SV; Kapoor P; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Dingli D; Kourelis T; Gonsalves W; Warsame R; Muchtar E; Leung N; Baughn LB; Kyle RA; Kumar S
    Blood Cancer J; 2021 Nov; 11(11):186. PubMed ID: 34836942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma.
    Steiner N; Hajek R; Sevcikova S; Borjan B; Untergasser G; Göbel G; Gunsilius E
    Anticancer Res; 2018 Sep; 38(9):5087-5092. PubMed ID: 30194153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quick consults in hematology: In support of active surveillance versus treatment of high-risk smoldering multiple myeloma outside of a clinical trial.
    Gertz MA
    Am J Hematol; 2024 Mar; 99(3):465-467. PubMed ID: 38115609
    [No Abstract]   [Full Text] [Related]  

  • 31. Necrobiotic Xanthogranuloma.
    Portuguese AJ; Long TH; Linenberger M
    Mayo Clin Proc; 2021 Sep; 96(9):2432-2434. PubMed ID: 34481598
    [No Abstract]   [Full Text] [Related]  

  • 32. Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.
    Correa JG; Cibeira MT; Tovar N; Isola I; Pedrosa F; Díaz T; Lozano E; Magnano L; Rosiñol L; Bladé J; Fernández de Larrea C
    Br J Haematol; 2017 Dec; 179(5):849-851. PubMed ID: 27605200
    [No Abstract]   [Full Text] [Related]  

  • 33. Smoldering Multiple Myeloma: Who and When to Treat.
    Mateos MV; González-Calle V
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):716-722. PubMed ID: 28709797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum markers alone can define high-risk smouldering multiple myeloma: new insights from the Czech Myeloma Group model.
    Sørrig R
    Br J Haematol; 2020 Jul; 190(2):137-138. PubMed ID: 32220013
    [No Abstract]   [Full Text] [Related]  

  • 35. Smoldering Myeloma and the Art of War.
    Lonial S; Dhodapkar MV; Rajkumar SV
    J Clin Oncol; 2020 Jul; 38(21):2363-2365. PubMed ID: 32463739
    [No Abstract]   [Full Text] [Related]  

  • 36. Timing of treatment of smoldering myeloma: early treatment.
    Mateos MV; González-Calle V
    Blood Adv; 2018 Nov; 2(21):3045-3049. PubMed ID: 30425068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical Implications.
    Biran N; Vesole DH; Donato ML; Ip A; Kaur G; Goldberg S; Siegel DS
    J Clin Oncol; 2020 Apr; 38(12):1367-1368. PubMed ID: 32160077
    [No Abstract]   [Full Text] [Related]  

  • 38. Early treatment for high-risk smouldering myeloma: has the time come?
    Ludwig H
    Lancet Oncol; 2016 Aug; 17(8):1030-1032. PubMed ID: 27402144
    [No Abstract]   [Full Text] [Related]  

  • 39. The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt.
    Mohyuddin GR; Ouchveridze E; Goodman A; Prasad V
    Leuk Lymphoma; 2021 Nov; 62(11):2793-2795. PubMed ID: 34114943
    [No Abstract]   [Full Text] [Related]  

  • 40. Should high risk smoldering myeloma be treated outside a clinical trial: NO.
    Gertz MA; Vaxman I
    Leuk Lymphoma; 2021 Nov; 62(11):2565-2567. PubMed ID: 34261405
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.